Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 2 , Pages 121-126 , June 2008

Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency

  • Rachela Popovtzer, PhD

      Affiliations

    • Department of Electrical Engineering – Physical Electronics and the TAU Research Institute for Nano Science and Nano-technologies, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • Tova Neufeld, PhD

      Affiliations

    • Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Aron Popovtzer, MD

      Affiliations

    • Davidov Cancer Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
    • ,
  • Ilia Rivkin, PhD

      Affiliations

    • Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Rimona Margalit, PhD

      Affiliations

    • Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Dikla Engel, MA

      Affiliations

    • Department of Chemistry, Bar-Ilan University, Ramat Gan, Israel
    • Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel
    • ,
  • Abraham Nudelman, PhD

      Affiliations

    • Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel
    • ,
  • Ada Rephaeli, PhD

      Affiliations

    • Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Beilinson Campus, Petach Tikva, Israel
    • ,
  • Judith Rishpon, PhD

      Affiliations

    • Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel
    • ,
  • Yosi Shacham-Diamand, PhD

      Affiliations

    • Department of Electrical Engineering – Physical Electronics and the TAU Research Institute for Nano Science and Nano-technologies, Tel-Aviv University, Tel-Aviv, Israel
    • Corresponding Author InformationCorresponding author. Department of Electrical Engineering – Physical Electronics and the TAU Research Institute for Nano Science and Nano-technologies, Tel-Aviv University, Tel-Aviv, Israel.

Received 31 October 2007 ,Accepted 20 March 2008.

References 

  1. Grigsby PW, Corn BW. Localized urethral tumors in women—indications for conservative versus exenterative therapies. J Urol. 1992;147:1516–1520
  2. McLeod H. Graying anatomy? Toward molecular tumor characterization. Pharmacogenomics. 2007;8:15–16
  3. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets. 2004;4:313–326
  4. Konski A, Feigenberg S, Chow E. Palliative radiation therapy. Semin Oncol. 2005;32:156–164
  5. Cao T, Heng BC. Differentiation therapy of cancer. Potential advantages over conventional therapeutic approaches targeting death of cancer/tumor cells. Med Hypotheses. 2005;65:1202–1203
  6. Miller SJ. Cellular and physiological effects of short-chain fatty acids. Mini Rev Med Chem. 2004;4:839–845
  7. Sell S, Pierce GB. Maturation arrest of stem-cell differentiation is a common pathway for the cellular-origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994;70:6–22
  8. Bell DR, Van Zant G. Stem cells, aging, and cancer: inevitabilities and outcomes. Oncogene. 2004;23:7290–7296
  9. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002;8:2142–2148
  10. Rephaeli A, Zhuk R, Nudelman A. Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications. Drug Dev Res. 2000;50:379–391
  11. Boren J, Lee WNP, Bassilian S, Centelles JJ, Lim S, Ahmed S, et al. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem. 2003;278:28395–28402
  12. Newmark H, Lipkin M. Omega-3 fatty acids and rectal epithelial-cell proliferation. Gastroenterology. 1994;107:1892–1894
  13. Comalada M, Bailon E, de Haro O, Lara-Villoslada F, Xaus J, Zarzuelo A, et al. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol. 2006;132:487–497[Erratum in: J Cancer Res Clin Oncol. 2007;133:211]
  14. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45:381–386
  15. Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, et al. The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs. 2006;24:383–392
  16. Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, et al. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer. 2005;116:226–235
  17. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953–R964
  18. Popovtzer R, Neufeld T, Ron EZ, Rishpon J, Shacham-Diamand Y. Electrochemical detection of biological reactions using a novel nano-bio-chip array. Sensors Actuators B, Chemical. 2006;119:664–672
  19. Entin-Meer M, Rephaeli A, Yang XD, Nudelman A, VandenBerg SR, Haas-Kogan DA. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther. 2005;4:1952–1961
  20. Engel D, Nudelman A, Tarasenko N, Makarovsky I, Chaplik I, Tarasenko I, et al. Novel prodrugs of tegafur with antiangiogenic properties and improved anticancer activity. Clin Cancer Res. 2005;11:9052S

PII: S1549-9634(08)00035-X

doi: 10.1016/j.nano.2008.03.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 2 , Pages 121-126 , June 2008

Article Tools

* Image Usage & Resolution